



## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.Q. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/666,629 09/18/2003		Gholam Peyman	PMAN / 24	9232	
26875 7	7590 03/13/2006	EXAMINER			
,	RRON & EVANS, LLP	FAY, ZO	FAY, ZOHREH A		
2700 CAREW	- <del>-</del>	ART UNIT	PAPER NUMBER		
441 VINE STREET			ARTONIT	PAPER NUMBER	
CINCINNATI, OH 45202			1618		
		DATE MAILED: 03/13/2006			

Please find below and/or attached an Office communication concerning this application or proceeding.

· ·			Application	No.	Applicant(s)			
Office Action Summary		10/666,629		PEYMAN, GHOLAM				
			Examiner		Art Unit			
			Zohreh A. Fa	y	1618			
Period fo	The MAILING DATE of this commun or Reply	nication appe	ears on the c	over sheet with the c	orrespondence ad	ldress		
WHIC - Exter after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR CHEVER IS LONGER, FROM THE Masions of time may be available under the provision: SIX (6) MONTHS from the mailing date of this composition of the properties of the provision of the maximum is the precision of the provision of the pro	MAILING DATES of 37 CFR 1.136 munication. tatutory period will by will, by statute, c	TE OF THIS  6(a). In no event,  Il apply and will excause the applica	COMMUNICATION however, may a reply be time control to become ABANDONEI	l. ely filed the mailing date of this o O (35 U.S.C. § 133).			
Status								
1)□	Responsive to communication(s) file	ed on						
'		2b)⊠ This a		-final.				
/	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is							
,_	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Dispositi	on of Claims							
4)🖂	Claim(s) 1-64 is/are pending in the	application.						
, —	4a) Of the above claim(s) <u>31-64</u> is/are withdrawn from consideration.							
	Claim(s) is/are allowed.							
•	Claim(s) <u>1-30</u> is/are rejected.							
-								
8)	Claim(s) are subject to restriction and/or election requirement.							
Applicati	on Papers							
9)□	The specification is objected to by the	ne Examiner.						
•	· ·		•	objected to by the B	xaminer.			
,	10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.								
Priority ι	ınder 35 U.S.C. § 119							
• —	Acknowledgment is made of a claim ☐ All b)☐ Some * c)☐ None of:		·		-(d) or (f).			
	1. Certified copies of the priority documents have been received.							
	2. Certified copies of the priority documents have been received in Application No							
	3. Copies of the certified copies of the priority documents have been received in this National Stage							
	application from the International Bureau (PCT Rule 17.2(a)).							
* 8	See the attached detailed Office action	on for a list o	f the certifie	d copies not receive	d.			
Amort	w->							
Attachment(s)  1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413)								
	e of References Cited (P10-892) e of Draftsperson's Patent Drawing Review (I	PTO-948)	4)	Paper No(s)/Mail Da				
3) 🛛 Inform	nation Disclosure Statement(s) (PTO-1449 or r No(s)/Mail Date			5) Notice of Informal Patent Application (PTO-152) 6) Other:				

Art Unit: 1618

Claims 1-30 are presented for examination.

The response to the restriction requirement of October 11, 2005 has been received and entered.

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-3, 9, 11-14 and 18 are rejected under 35 U.S.C. 102 (b) as being anticipated by Schachar (U.S. Patent 4,620,979). Schachar teaches the use of vitamin C in combination with a stabilizing agent, such as glutathione at the claimed concentrations. See claims 1-8 and the abstract.

Claims 4, 6, 8, 20 are rejected under 35 U.S.C. 102 (b) as being anticipated by Ghosal (U.S. Patent 6,235,721). Ghosal teaches the use of vitamin C in combination with Emblica officinalis fruit extract and propylene glycol in a pharmaceutical formulation. See example 20 and column 2, lines 1-12.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.

4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 5, 6, 7, 10, 15, 16, 17, 19, and 21-30 are rejected under 35 U.S.C. 103(a) as being unpatentable over Schachar (U.S. Patent 4,620,979) and Petrus (U.S. Patent 6,573,299).

Schachar teaches the use of vitamin C in combination with glutathione in an ophthalmic formulation. See claims 1-8 and the abstract. The above reference differs from the claimed invention in the use of cysteine as a stabilizing agent and the additives such as silicone and polymers. Petrus teaches that the cysteine derivatives have been previously used in combination with ascorbic acid and glutathione. See column 9, lines 51-55. The above reference also teaches the use of silicone and selenium as additives in ophthalmic formulations as old and well known. See column 14, lines 20-35 and table 1. It would have been obvious for a person skilled in the art to use a cysteine as a stabilizer and silicone and polymers as additive with the composition of the primary reference, considering that Petrus teaches the use of a cysteine in combination with ascorbic acid as old. Petrus also teaches the use of additives such as silicone and selenium in ophthalmic formulations as old.

One skilled in the art would have been motivated to combine the teachings of the above references, since one relates to the use of ascorbic acid in combination with the antioxidant glutathione in a pharmaceutical formulations, and the other relates to the use of ascorbic acid derivatives in combination with cysteine derivatives in an ophthalmic composition with the claimed additives such as silicone and selenium. The above references in combination make clear that ascorbic acid has been previously

used with the claimed anti-oxidants. The determination of optimum proportion or amounts is considered to be within the skill of the artisan. The use of the conventional ophthalmic additive is also considered to be within the skill of the artisan. Applicant has presented no evidence to establish the unexpected or unobvious nature of the claimed invention, and as such, the above claims are properly rejected under 35 U.S.C. 103.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Zohreh A. Fay whose telephone number is (571) 272-0573. The examiner can normally be reached on Monday to Friday 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Hartley can be reached on (571) 272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

ZOHREH FAY RIMARY EXAMINER GROUP 1200

POST TO THE PROPERTY OF THE PR

Z.F